Earlier studies revealed that human interleukin 6 (IL-6) contains recognition sites for the hepatitis B virus (HBV) envelope (env) protein, and that IL-6 and anti-Ib6 antibodies, respectively, inhibited the interaction of ceils expressing a receptor for HBV with the preS(21-47) segment of the HBV env protein, encompassing the complementary attachment site for IL-6. This suggested that IL-6 mediates HBV-cell interactions. We report that: (a) Chinese hamster ovary cells transfected with human IL-6 cDNA and Spodoptera frugiperda ovarian insect cells infected with recombinant baculovirus carrying human Ib6 cDNA expressed receptors for the preS(21-47) region of the HBV env protein, indicating that expression of IL-6 on the surface of calls is sufficient to endow them with receptors for HBV. 
H
epatitis B virus (HBV) 1 is a major human pathogen implicated in primary hepatocarcinoma. The envelope (env) of the virus consists of three related proteins (S, M, and L) that are all products of a single env gene. These proteins share a common 226-residue COOH-terminal amino acid sequence (S protein). M protein has an additional 55-amino acid sequence located at the NH2 terminus (preS2 sequence). L protein differs from M protein by an additional NHz-terminal 108-or 119-amino acid sequence designated as preS1. A segment of the preS1 sequence encompassing amino acid residues 21-47 is involved in the attachment of HBV to human hepatoma HepG2 cells (1) and to isolated human liver plasma membranes (2--4) . The presence of receptors for the preS(21-47) region of the HBV env protein was demonstrated also on cells of nonhepatic origin, including PBL (5, 6) , representing, in addition to the liver, target cells for HBV (7) (8) (9) .
The preS(21-47) region of the HBV env protein encore- passes a binding site for Ib6 (6) . The following findings indicated that cell-associated Ib6 mediates the interaction between the preS1 region of the HBV env proteins and ceils of hepatic or extrahepatic origin: (a) this interaction was inhibited by Ib6 and by anti-IL-6 antibodies; (b) stimulation of T cells and PBMC with Con A and LPS, respectively, induced the production of both IL6 and of recognition sites for the preS1 region of the HBV env protein; and (c) exposure of Ib6-producing cells to phosphatidylinositol-specific phospholipase C (PI-PLC) or to low pH resulted in the release of cell-associated IL-6 and in reduced cell binding to the preSl(21-47) ligand (6) . These results suggested that cellassociated Ib6 either represented a cell surface receptor for HBV or a constituent of a multicomponent receptor complex. This report provides direct evidence that cell surface-associated II.-6 is sufficient to endow cells with binding activity for the preS1 region of the HBV env protein by demonstrating that nonhuman cells transfected with human Ib6 cDNA acquired receptors for HBV. Furthermore, regions on the IL-6 protein essential for recognition of the preS(21--47) ligand were delineated, and amino acid residues within the preS(21-47) region essential for cell receptor binding were identified.
Materials and Methods
Cells Extrressing Human 11, 6 . The following cell lines were used: Peptide Synthesis. Peptides from the preS region of the HBV env protein, preS , preS , and preS(21--47), were synthesized and linked to cellulose as described before (1, 5, 6) . Replacement setpeptides from the preS(21-47) sequence were synthesized on a multiple-peptide synthesizer (350 MPS; Advanced ChemTech, Louisville, KY) using 1,3-diisopropylcarbodiimide and 1-hydroxybenzotriazole activation in a 9-fluorenyl-methoxycarbonyl (Fmoc)-mediated synthesis. The peptides were cleaved off the resin by TFA/thioanisole/ethanedithiol/anisole (90:5:3:2) for 4 h. The peptide-resin mixtures were freeze dried and the peptides were extracted from the resin with 20% acetic acid. Each of the peptides was purified on a C18 reverse-phase column with a linear 0.1% TFA/H20-100% acetonitrile gradient. Fractions corresponding to the major peak of absorbance at 214 nm were lyophilized and used for the experiments described below. To confirm the correctness of the sequence, the peptide with no substitutions and the peptide with proline at position 47 replaced by alanine were sequenced on a sequencer (477A/120A; Applied Biosystems, Inc., Foster City, CA). The sequences were proven to be correct. All peptides were synthesized in the form of amides and had a glycine-glycine-cysteine spacer at the COOH terminus. The NH2 terminus of each peptide was acetylated.
Peptides from the sequence of Ib6 were synthesized in the form of amides on a peptide synthesizer (9600; MilliGen/Biosearch, Milford, MA) using benzotriazolyloxytris (dimethylamino) phosphonium hexafluorophosphate and 1-hydroxybenzotriazole activation in a Fmoc-mediated synthesis following Technical Bulletin no. 900-03 from Biosearch. Peptide cleavage was accomplished as described above. The peptides were precipitated with diethyl ether and lyophilized. When submitted to reverse-phase chromatography on C18 columns using a linear gradient as described above, a single major absorbance peak at 214 nm was discernible. The sequence of each peptide was confirmed by direct sequencing.
Immunofluorescence. Cell-bound human IL-6 was determined by indirect immunofluorescence. 106 CHO or CHO-IL-6 cells pelleted and prewashed with PBS containing 10 mg/ml BSA (PBS-BSA) were mixed with 100 #1 PBS containing 5% normal goat serum (PBS-NGS) and with either control normal mouse IgG or with anti-human Ib6 mAb (10/~g in 100/zl; Genzyme, Cambridge, MA). After 45 rain at 4~ the cells were washed three times with 1 ml PBS-BSA. Subsequently, 50/~1 of FITC-labeled goat F(ab')2 anti-mouse IgG (Tago, Inc., Burlingame, CA), diluted to 3.5/zg/ml in PBS-NGS, was added in the dark for 30 min at 4~ The cells were washed three times with cold PBS and then resuspended in 400/~1 of 1% formaldehyde in PBS. Flow cytometry analysis was then performed in FACS IV ~ or FACScan | flow cytometers (Becton Dickinson Immunocytometry Systems, San Jose, CA). Surface expression of I1.-6 on B-IL-6 cells was measured under similar conditions, except that the cells were preincubated for 30 min at 25~ with brefeldin A (4/zg/ml; Boehringer Mannheim Biochemicals, Indianapolis, IN) to inhibit secretion of II., 6 (11, 12) , and that Graces' medium was used instead of PBS-BSA.
Preparation and Testing of Antit~tide Antisera. Two NZW rabbits were immunized with 200/~g of the respective peptides from IL-6 (see Fig. 4 ) in unconjugated form in combination with CFA. The rabbits were boosted with 200-/~g doses of peptides in combination with IFA in biweekly intervals. 2 wk after each immunization, blood samples were taken and analyzed for antibodies by ELISA. 8-10 wk after the initial immunization, the rabbits were killed after collecting blood by cardiac puncture.
Wells of 96-well polystyrene plates (Immulon II; Dynatech Laboratories, Inc., Chantilly, VA) were coated either with purified IL-6 (500 ng/well) produced by CHO-Ib6 cells or with the respective synthetic peptides from IL-6 (4/zg/well; 200/zl in 0.1 M Tris, pH 8.8) overnight at 20~ The wells were postcoated with BSA and gelatin (10 and 2.5 mg/ml, respectively). Control as well as antipeptide antisera were serially diluted (starting dilution, 1:t>20) in a mixture of FCS and goat serum (9:1), 0.1% Tween 20, adjusted to pH 8.0 (BG). The diluted sera (200/zl) were added to IL-6-or peptide-coated wells and incubated overnight at 25~ The wells were washed with 0.14 M NaC1, 0.01 M Tris, 0.01% sodium merthiolate, pH 7.2 (TS). Subsequently, the wells were incubated with goat anti-rabbit IgG linked to horseradish peroxidase (Boehringer Mannheim Biochemicals) (diluted 1:1,000 to 1:2,000 in TS containing 5% normal goat serum and 0.05% Tween 20). After incubation for 2 h at 37~ the wells were washed with TS, and peroxidase activity bound to the wells was determined using a kit from Kirkegaard & Perry Laboratories, Inc. (Gaithersburg, MD). Absorbance at 450 nm was determined in a microplate reader (MR600; Dynatech Laboratories, Inc.). Dilution endpoints corresponding to the highest dilution at which the ratio of absorbance corresponding to positive samples divided by absorbance corresponding to equally diluted normal sera was >--2.1 were calculated as described by Ritchie et al. (15) . ELISAs with mouse anti-Ib6 mAbs (Genzyme, Cambridge, MA) were carried out under similar conditions, except that horseradish peroxidase-labeled anti-mouse instead of anti-rabbit, IgG was used. Cellulose. PreS(21-47) cellulose was prepared as described before (1, 6) . Magnetic beads with bound anti-IL-6 mAb were prepared as follows: magnetic beads with covalently attached goat anti-mouse IgG (300 #1; Advanced Magnetics, Inc., Cambridge, MA) were mixed with 50/~g of mouse anti-Ib6 mAb overnight at 4~ Unadsorbed antibodies were removed, the beads were washed four times with PBS, and resuspended in 300 ~1 of"IS. The attachment of HepG2, CHO, CHO-IL-6, and of SD insect cells, either uninfected or infected with wild-type or recombinant bacnloviruses, to preS(21-47) cellulose and anti-IL-6 magnetic beads, respectively, was quantitated as described before (6) . In some cases, the cells were pretreated with brefeldin A (4/~g/ml) for 30 rain either at 37~ (CHO-Ib6 cells) or at 25~ (SD cells) to inhibit secretion of Ib6. Conditions for treating cells with PI-PLC or at pH4 were the same as already described (6) .
Binding of CeUs to Anli-IL.6 Magnetic Beads and to trreS
The inhibitory effect of antisera to peptides from IL-6 (final dilution, 1:10) and of peptides from IL-6 and from the preS(21-47) sequence (final concentration, 2 mg/ml), respectively, was followed by adding the respective substances to cell-preS(21-47) cellulose mixtures, otherwise following conditions described above.
Results

Expression of ll.,6 eDNA in Cells Endows Them with Receptors for the preSl Region of the HBV env Protein. To determine
whether or not the biosynthesis of human IL-6, but of no other human gene products, is sufficient for expression of call receptors for the preS(21-47) region of the HBV env protein, cells transfected with IL-6 eDNA or infected with a recombinant baculovirus with inserted IL-6 eDNA were assayed for the presence of HBV receptors. CHO-IL-6 cells secreted relatively large quantities of Ib6 ('~250 /zg/107 cells/72 h). SD cells, derived from S. frugiperda ovarian cells, infected with recombinant baculovirus carrying IL-6 eDNA, produced "~1% of that amount of II.-6. IL-6 was detectable on the surface of each of these cell lines by cytofluorometry (Fig. 1) . Ib6 was not detectable on the surface of CHO cells and of uninfected SD cells.
The surface expression of Ib6 on CHO-II.-6 cells was confirmed by the observation that these cells adsorbed to magnetic beads with attached anti-II.-6 mAbs (Fig. 2 A) . CHO-II.,6 calls did not bind to control magnetic beads carrying normal mouse IgG. Control CHO cells bound to the anti-IL-6 beads nonspecifically to a much lesser extent that CHO-IL,6 cells. Pretreatment of CHO-IL-6 cells with PI-PLC resulted in their decreased binding to anti-IL-6 beads. Pretreatment at pH 4 had a minimal effect on the binding of these cells to anti-IL-6 beads. CHO-Ib6 calls, unlike CHO cells, also bound to preS(21-47) cellulose (Fig. 2 B) . Treatment of the calls with either PI-PLC or at pH 4 resulted in decreased binding to the ceUulose derivative. These results demonstrate that surface expression of human IL-6 on calls of nonhuman origin resulted in appearance of binding sites for the preS (21- bound also to cellulose with covalently linked hepatitis B surface antigen (HBsAg) containing the preS1 sequence but not to control cellulose with covalently linked BSA or the peptide preS(12-32) (data not shown).
To confirm that decreased binding to preS(21-47) cellulose of CHO-IL-6 cells pretreated with PI-PLC or at pH 4 can indeed be attributed to release of II.-6 from these cells, Ib6 was measured in the supernatant fluids after treating the cells. Similar levels of II.-6 were found in cells treated by either method and in mock-treated cells. This was due to continued secretion of II-6 from the cells during the 30-rain treatment period. To block the secretion of IL-6, the cells were pretreated with brefeldin A and subsequently exposed to either PI-PLC or to pH 4. Under these conditions, significant differences in the release of IL-6 between PI-PLC-, pH 4-, and mock-treated cells were observed (Fig. 2 C) . Thus, decreased binding to preS (21- the medium (Fig. 3 C) and in diminution of surface-exposed I1.-6 and of binding sites for the preS(21-47) ligand.
In summary, these results indicate that expression of human IL-6 in cells, independent of their origin, also leads to the expression of receptors for the preS1 region of the HBV env protein.
Delineation of Binding Sites on IL6 for the preS(21-47) Region of the HBV env Protein. Since the preS(21-47) region of the HBV sequence was recognized by IL-6 both in solution and in cell-associated form (6), it was of interest to define the preS1 binding domain on the Ib6 protein. To accomplish this, the inhibitory effect of synthetic peptides from the IL-6 sequence (Fig. 4) , and of the corresponding antipeptide antisera on the binding of HepG2 cells to preS(21-47) cellulose, was investigated. Synthetic peptides covering the entire sequence of IL-6, except the peptide corresponding to the signal sequence, reacted with a polyclonal rabbit anti-Ib6 antiserum (Fig. 5 A) (Fig. 5 B) . However, the titer of antibodies recognizing Ib6 was generally lower than that of antibodies reacting with the respective homologous peptides, in agreement with the conclusion that the immunological crossreactivity between Ib6 and synthetic peptides from Ib6 was partial. Since the synthetic peptides from Ib6 at least partially mimicked the corresponding region on the Ib6 protein at the level of immunological recognition, it was expected that they might also be suitable for delineating the preS(21-47) binding site within the Ib6 amino acid sequence. Among the 1I:6 peptides tested for inhibitory activity on the interaction between HepG2 cells and preS(21-47) cellulose, peptide appeared to be the most effective (Fig. 6 A) . Peptides and were less effective in this respect. However, on molar basis, peptide had only ,~1/5,000 of the inhibitory activity of I1:6 (6). All other peptides lacked inhibitory activity. Reduced and alkylated peptide had no inhibitory activity, indicating that cysteine residues 44 and 50 (Fig. 4 A) , and possibly a disulfide bond between them, were essential for inhibitory activity. Among the antipeptide antisera tested, only anti-J35-66] significantly inhibited the binding of HepG2 cells to preS(21-47) cellulose (Fig. 6  B) . In summary, assaying of peptides from I1:6 and of the corresponding antipeptide antisera for inhibition of binding of HepG2 cells to preS(21-47) cellulose suggested that the region of the I1:6 sequence overlaps a complementary site for the preS(21-47) segment on the HBV env preS1 sequence. This conclusion was further supported by results of epitope mapping of anti-Ib6 mAbs (Fig. 7) , shown before (6) to inhibit the interaction between the HBV env protein and HepG2 cells. (having an antibody dilution endpoint of 1:102,400 as measured by ELISA on IL-6-coated plates) and a control normal rabbit serum, respectively, were serially diluted in BG and added to wells of polystyrene plates coated with peptides covering the entire sequence of II26 (see Fig. 4 ). After overnight incubation at 20"C, the wells were washed, and rabbit IgG bound to the wens was determined by F_LISA using horseradish peroxidase-hbeled goat anti-rabbit IgG. The dilution endpoints of anti-IL-6, corresponding to the highest dilution at which the OD450 readings corresponding to bound IgG from the anti-IL-6 serum were 2.1 times higher than that corresponding to bound IgG from the control normal rabbit serum, were calculated and plotted. (B) Serial dilutions in BG of rabbit antisera against distinct peptides from the sequence of IL,6 were added to wells coated either with the homologous peptides (4 #g/well) or with rIL-6 (500 rig/well). Control experiments were carried out with dilutions of normal rabbit serum. Antibody dilution endpoints were determined as described for A. For further details, see Materials and Methods. molecular details of the interaction between the HBV env protein and Ib6, the cell receptor binding site for HBV, it was important to determine which amino acid residues on the complementary sequences are essential for the binding reaction to occur. Since the mimicry of the preS1 region, involved in this interaction, by the synthetic peptide preS(21-47) was more complete (16) than that of the complementary II.-6 sequence by the IL-6 peptide (Figs. 5 and 6 ), we decided to initiate such studies by first measuring the activity of replacement set peptides from the preS(21-47) sequence. Alanine replacement set peptides corresponding to this sequence were synthesized, and their inhibitory effect on the attachment of HepG2 cells to pre.S(21-47) cellulose was studied. The results revealed that residues 21-25, 28, 31, 34, 35, 39, and 43-45 could all be replaced by alanine (A), and that the A residue at position 33 could be replaced by serine (S) without impairing the inhibitory activity of the peptides (Fig. 8) . All other replacements, including substitutions of four proline residues at positions 26, 32, 41, and 47, had a deleterious effect.
Identification of Amino Acid Residues within the preS(21-47) Sequence Essential for Recognition by the
Identification of essential amino acid residues within the IL-6 sequence, possibly corresponding to contact residues involved in the IL-6-HBV env protein interaction, will require the design of synthetic molecules mimicking the binding site for the preS(21-47) region with greater fidelity than the peptide from I1.-6. The design of such mimetics may contribute to the development of antiviral agents against HBV.
Discussion
Results of earlier studies (6) . ====~==- [35- or their exposure to pH 4 resulted in release of I1:6 and in decreased binding activity for the preS(21-47) ligand, as was observed earlier with human cells expressing I1"6 either constitutively or after activation (6). I1:6 released by PI-PLC from HepG2 cells or from I1:6-c-DNA-transfected cells had a molecular mass similar to that of I1:6 secreted into the medium (23-30 kD), as determined by immunoblotting after electrophoresis in polyacrylamide gels under reducing and denaturing conditions (our unpublished data), in agreement with other reports (17, 18) . In addition to ,~27-kD species, less abundant larger molecular mass forms of I1:6 ("o47-89 kD) were discerned under nondenaturing conditions by molecular exclusion chromatography on Sephadex G-150 for PI-PLC-released I1:6, as well as for I1:6 secreted either from HepG2 cells or from transfected cells (our unpublished data), in agreement with results reported by May et al. (17, 19) . These results suggest that PI-PLC-released I1:6 is predominantly not associated with another carrier protein(s) or that possible complexes of IL-6 with other proteins are dissociated during molecular exclusion chromatography, suggesting a weak binding between I1:6 and a putative carrier molecule. A possible association between I1-6 and mannose binding proteins has been recently suggested (20) . The mechanism whereby I1:6 becomes released by PI-PLC from cells remains to be elucidated, since the COOH terminus of I1:6 does not fulfill the sequence requirements needed for attachment of a phosphatidylinositol glycan (13, 14, 21) . ri1:6 produced in E. coli lacking saccharide residues, unlike I1-6 from eukaryotic cells (17, 18, 22) , also had binding sites for the preS(21-47) region of the HBV L protein and inhibited the attachment of HepG2 cells to preS(21-47) cellulose (our unpublished data). This indicated that the binding site for the preS(21-47) ligand is located on the protein moiety of Ib6, offering the opportunity to locate this site within the II.,6 sequence using synthetic peptides from Ib6. Among peptides covering the entire sequence of I1:6 and the corresponding antipeptide antibodies, peptide and the homologous anti-J35-66] antipeptide antiserum were the most effective in inhibiting the attachment of HepG2 cells to preS(21-47) cellulose. These results suggest that the segment of the I1:6 sequence is part of a binding site for the preS1 region of the HBV env protein, although other regions of the II:6 sequence appear to contribute directly or indirectly (through conformational effects) to this binding site.
Studies with point and deletion mutants of I1:6 and with mAbs of defined specificity suggested that the COOHterminal portion of I1:6 encompassing residues [151-183] is essential for biological activity and contains the I1:6R binding site (23) (24) (25) (26) . On the other hand, studies with NH2-terminally deleted mutants suggested that residues [29] [30] [31] [32] [33] [34] are essential for biological activity of I1:6, while residues could be deleted without affecting activity (27) . Cumulatively, these results suggest that both the COOH-and NH2-terminal regions are essential for biological activity of this cytokine (28) . Any internal deletions within the sequence of II-6, reported to result in loss of biological activity (28) , probably prevent the proper folding of I1-6. This agrees with the experimentally determined or proposed structures for four helix bundle cytokines, including I1:6 (29-33). The binding site for the preS(21-47) ligand, tentatively assigned to a region of I1-6 encompassing residues , is likely to be distinct from the I1-6R binding site assigned to residues [178-183] (25) . The distinctiveness of preS(21-47) and I1"6R binding sites is also suggested by the observation that the inhibitory activity of the I1:6 peptide on attachment of HepG2 cells to the preS(21-47) ligand is abolished after reduction and alkylation of cysteine residues 35 and 50, while a mutant II.-6 protein in which all four cysteine residues are replaced by serines was reported to retain biological activity (34) . This raises the possibility of developing antiviral compounds mimicking the receptor binding site for HBV on Ib6 but not displaying undesirable biological effects of the intact Ib6 molecule. In this respect, it also appears important to note that: (a) there is no significant sequence homology between the preS(21-47) ligand and ID6R (35) , and the Ib6 signal transducer g'p130 (36), respectively; (b) the interaction of HepG2 cells and of other cells expressing the receptor for the preS1 region of the HBV env protein with the preS(21-47) ligand (5) and binding of rlI.,6 to the HBV L protein or to the synthetic peptides preS(12--47) and preS(21--47), respectively, required the presence of Ca 2 § ions (6, our unpublished data), while there is so far no evidence that the biological activity of I1--6 is manifested only at the presence of Ca 2+. Notwithstanding the Ca 2 § dependence of the Ib6-preS(21-47) association, consensus sequences characteristic for calcium binding proteins could be recognized on neither the I1.-6 or the preS1 sequences.
Association between Ib6 exposed on the surface of cells and the preS1 region of the HBV env L protein is probably an important, but possibly not sufficient, step for entry of HBV into cells, resulting in initiation of the virus replication cycle. Additional cell receptor binding sites (37, 38) and dividing target cells (39) may be required for virus replication. Transfection of nonhuman cells with cDNAs coding for human cellular proteins may help identify steps required for the life cycle of HBV. Cells transfected with human II.-6 cDNA and expressing receptors for the preS1 region of the HBV env protein represent a step towards accomplishing this goal.
